JP2014526519A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526519A5
JP2014526519A5 JP2014530924A JP2014530924A JP2014526519A5 JP 2014526519 A5 JP2014526519 A5 JP 2014526519A5 JP 2014530924 A JP2014530924 A JP 2014530924A JP 2014530924 A JP2014530924 A JP 2014530924A JP 2014526519 A5 JP2014526519 A5 JP 2014526519A5
Authority
JP
Japan
Prior art keywords
range
pharmaceutical composition
mdj
nanocarriers
size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014530924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014526519A (ja
Filing date
Publication date
Priority claimed from PCT/IB2012/000364 external-priority patent/WO2012114196A1/pt
Application filed filed Critical
Priority claimed from PCT/US2012/055757 external-priority patent/WO2013040556A1/en
Publication of JP2014526519A publication Critical patent/JP2014526519A/ja
Publication of JP2014526519A5 publication Critical patent/JP2014526519A5/ja
Pending legal-status Critical Current

Links

JP2014530924A 2011-09-16 2012-09-17 ジャスモネート化合物の組成物および使用方法 Pending JP2014526519A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201161535836P 2011-09-16 2011-09-16
US61/535,836 2011-09-16
US201161555690P 2011-11-04 2011-11-04
US61/555,690 2011-11-04
US201261603042P 2012-02-24 2012-02-24
US61/603,042 2012-02-24
PCT/IB2012/000364 WO2012114196A1 (pt) 2011-02-25 2012-02-27 Formulação farmacêutica compreendendo compostos da família dos jasmonatos
IBPCT/IB2012/000364 2012-02-27
US201261607318P 2012-03-06 2012-03-06
US61/607,318 2012-03-06
US201261612774P 2012-03-19 2012-03-19
US61/612,774 2012-03-19
PCT/US2012/055757 WO2013040556A1 (en) 2011-09-16 2012-09-17 Compositions of jasmonate compounds and methods of use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2017117103A Division JP2017222659A (ja) 2011-09-16 2017-06-14 ジャスモネート化合物の組成物および使用方法
JP2019000256A Division JP2019077702A (ja) 2011-09-16 2019-01-04 ジャスモネート化合物の組成物および使用方法

Publications (2)

Publication Number Publication Date
JP2014526519A JP2014526519A (ja) 2014-10-06
JP2014526519A5 true JP2014526519A5 (enExample) 2015-11-12

Family

ID=47883826

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014530924A Pending JP2014526519A (ja) 2011-09-16 2012-09-17 ジャスモネート化合物の組成物および使用方法
JP2017117103A Pending JP2017222659A (ja) 2011-09-16 2017-06-14 ジャスモネート化合物の組成物および使用方法
JP2019000256A Pending JP2019077702A (ja) 2011-09-16 2019-01-04 ジャスモネート化合物の組成物および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017117103A Pending JP2017222659A (ja) 2011-09-16 2017-06-14 ジャスモネート化合物の組成物および使用方法
JP2019000256A Pending JP2019077702A (ja) 2011-09-16 2019-01-04 ジャスモネート化合物の組成物および使用方法

Country Status (11)

Country Link
US (3) US8883220B2 (enExample)
EP (1) EP2755643B1 (enExample)
JP (3) JP2014526519A (enExample)
KR (2) KR102023132B1 (enExample)
CN (2) CN104203222A (enExample)
BR (1) BR112014006153A2 (enExample)
CA (1) CA2848219A1 (enExample)
HK (1) HK1254825A1 (enExample)
MX (1) MX370253B (enExample)
RU (1) RU2014114931A (enExample)
WO (1) WO2013040556A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2679230A4 (en) * 2011-02-25 2014-07-23 Nanocare Technologies Inc PHARMACEUTICAL FORMULATION WITH JASMONATE FAMILY COMPOUNDS
BR112014006153A2 (pt) * 2011-09-16 2020-12-01 Nanocare Technologies, Inc. composição farmacêutica, e, método para tratar um distúrbio
JP2014122191A (ja) * 2012-12-21 2014-07-03 L'oreal Sa 油、非イオン界面活性剤及びジャスモン酸誘導体を含む化粧品組成物
CN104902864B (zh) 2012-12-21 2020-09-01 莱雅公司 化妆品组合物
US20150230462A1 (en) * 2014-01-15 2015-08-20 New Biology, Inc. Methods for improving germination and stress tolerance characteristics with jasmonates
US10314918B2 (en) 2014-12-31 2019-06-11 Nanocare Technologies, Inc. Jasmonate derivatives and compositions thereof
US20200297620A1 (en) * 2016-03-28 2020-09-24 Vidac Pharma Ltd Stable pharmaceutical compositions for topical administration and uses thereof
US10410943B2 (en) 2016-10-13 2019-09-10 Asm Ip Holding B.V. Method for passivating a surface of a semiconductor and related systems
WO2018083704A1 (en) 2016-11-07 2018-05-11 Vidac Pharma Ltd. Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses
US11266639B2 (en) * 2016-11-07 2022-03-08 Vidac Pharma Ltd. Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (HK2)-expressing cancers
US20210161842A1 (en) * 2018-04-12 2021-06-03 Vytrus Biotech, S.L. Abscisic acid for the treatment of skin diseases
KR102275801B1 (ko) * 2019-12-24 2021-07-09 경희대학교 산학협력단 시스-자스몬을 포함하는 바이오필름 형성 억제용 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0392608T3 (da) 1989-04-12 1995-11-20 Procter & Gamble Faste konsumentproduktsammensætninger, der indeholder cyclodextrinkomplekser af lille partikelstørrelse
CA2013485C (en) 1990-03-06 1997-04-22 John Michael Gardlik Solid consumer product compositions containing small particle cyclodextrin complexes
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
JP3568325B2 (ja) * 1996-07-12 2004-09-22 株式会社ノエビア 抗アンドロゲン剤及び養毛剤並びに毛髪用化粧料
JP3596835B2 (ja) 1996-08-13 2004-12-02 株式会社ノエビア 養毛剤
EP0988025A1 (en) 1997-06-09 2000-03-29 The Procter & Gamble Company Perfumed compositions and methods for reducing body odors and excess moisture
US6790815B1 (en) 1998-07-10 2004-09-14 Procter & Gamble Company Amine reaction compounds comprising one or more active ingredient
CA2274873A1 (en) 1999-07-06 2001-01-06 Satinder Gidda Methods and compositions for modulating flowering
WO2002072011A2 (en) 2001-03-08 2002-09-19 Targesome, Inc. Stabilized therapeutic and imaging agents
US6469061B1 (en) * 2001-04-04 2002-10-22 Ramot University Authority For Applied Research And Industrial Development Limited Jasmonate pharmaceutical composition for treatment of cancer
US20030224024A1 (en) 2002-02-04 2003-12-04 Jean-Luc Leveque Compositions comprising cyclopentane derivatives and their use
US20040209795A1 (en) * 2003-04-21 2004-10-21 Vlad Florin Joseph VOC-free microemulsions
CA2548173A1 (en) 2003-12-02 2005-06-16 Eliezer Flescher Jasmonate derivative compounds, pharmaceuticals compositions and methods of use thereof
KR100789343B1 (ko) 2004-09-07 2007-12-28 주식회사 엘지생활건강 화장용 분체, 그의 제조방법 및 이를 함유하는 메이컵화장품 조성물
EP1814894B1 (de) 2004-11-25 2012-08-08 Merck Patent GmbH Flavonoid-komplexe mit cyclodextrinen
US7258878B2 (en) 2004-12-20 2007-08-21 Kimberly-Clark Worldwide, Inc. Anti-microbial composition and methods of use thereof
ES2265291B1 (es) 2005-07-22 2008-03-01 Universidad De Alcala Nuevos dendrimeros carbosilanos, su preparacion y sus usos.
WO2007066336A2 (en) 2005-12-07 2007-06-14 Ramot At Tel Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
EP1968959A2 (en) 2005-12-07 2008-09-17 Sepal Pharma Ltd. Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
US20070207981A1 (en) 2006-03-06 2007-09-06 Eva Almenar Micro-encapsulation of volatile compounds into cyclodextrins: a new technology to reduce post harvest losses
US20090185985A1 (en) 2006-06-13 2009-07-23 Cargill, Incorporated Large-particle cyclodextrin inclusion complexes and methods of preparing same
AU2007273809A1 (en) 2006-07-10 2008-01-17 Ramot At Tel-Aviv University Ltd. Combination methods of treating cancer
BRPI0604024A (pt) 2006-09-01 2008-04-22 Beyond Lifescience Pesquisa De alimentos para a prevenção do cáncer e composições farmacêuticas à base do jasmonato
EP2049083A2 (en) 2006-12-27 2009-04-22 Cargill, Incorporated Stabilisation by preparing cyclodextrin inclusion complexes
WO2009019693A2 (en) * 2007-08-07 2009-02-12 Sepal Pharma Sa Analgesic effect of jasmonate derivatives
HUE043897T2 (hu) 2007-09-25 2019-09-30 Solubest Ltd Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra
GB0721761D0 (en) 2007-11-06 2007-12-19 Plant Bioscience Ltd Compositions and methods for synergistic manipulation of plant and insect defences
WO2009067404A2 (en) * 2007-11-19 2009-05-28 New Biology, Inc. Methods for improving flowering characteristics using methyl dihydrojasmonate
US20090197939A1 (en) * 2008-02-01 2009-08-06 Mary Kay Inc. Methods of treating skin with aromatic skin-active ingredients
ES2328002B2 (es) 2008-02-29 2010-03-29 Universidad De Alicante Uso combinado de metil-jasmonato y ciclodextrinas para la produccion de resveratrol.
BRPI0804172A2 (pt) * 2008-07-15 2010-07-06 Pereira Lopes Jose Emilio Fehr compostos quìmicos formados a partir de nanoencapsulamentos e complexação de elementos
US20120083529A1 (en) * 2009-06-09 2012-04-05 Sepal Pharma Ltd Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
CN101818100B (zh) * 2010-04-15 2012-06-06 上海应用技术学院 聚氰基丙烯酸丁酯包覆大花茉莉香精胶囊的制备方法
EP2609064B1 (en) 2010-08-27 2016-09-28 Neonc Technologies Inc. Pharmaceutical compositions comprising derivatives of perillyl alcohol
EP2679230A4 (en) 2011-02-25 2014-07-23 Nanocare Technologies Inc PHARMACEUTICAL FORMULATION WITH JASMONATE FAMILY COMPOUNDS
BR112014006153A2 (pt) 2011-09-16 2020-12-01 Nanocare Technologies, Inc. composição farmacêutica, e, método para tratar um distúrbio
EP2583998B1 (en) * 2011-10-21 2018-02-28 Borealis AG Polyethylene composition with high rapid crack propagation resistance and pressure resistance
US9187402B2 (en) 2012-06-14 2015-11-17 North Carolina Agricultural And Technical State University Aspirin derivatives and uses thereof
WO2014009429A1 (en) 2012-07-10 2014-01-16 Ludwig-Maximilians-Universität München Anandamide-modified nucleic acid molecules
US10314918B2 (en) 2014-12-31 2019-06-11 Nanocare Technologies, Inc. Jasmonate derivatives and compositions thereof

Similar Documents

Publication Publication Date Title
JP2014526519A5 (enExample)
Zinchenko et al. Single-chain compaction of long duplex DNA by cationic nanoparticles: modes of interaction and comparison with chromatin
HRP20200256T1 (hr) Čestice bilirubina i njihova priprema za uporabu u liječenju
JP2012085643A5 (enExample)
JP2011525477A5 (enExample)
JP2014513036A5 (enExample)
ATE541909T1 (de) Klebstoff
JP2014523540A5 (enExample)
CO6300931A2 (es) Composiciones farmaceuticas que comprenden particulas de liberacion controlada con un nucleo que comprende farmacos levemente basicos
BRPI1013021A2 (pt) "material compósito que compreende nanopartículas, e produção de camadas fotoativas que contêm nanopartículas semicondutoras quaternárias, pentanárias ou de ordem mais alta"
JP2013535021A5 (enExample)
CR20150077A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
RU2014114931A (ru) Композиции соединений жасмонатов и способы применения
JP2013047264A5 (enExample)
JP2014514361A5 (enExample)
JP2014520836A5 (enExample)
JP2013511602A5 (enExample)
RU2016103313A (ru) Липидная наночастица с полимиксином
JP2013516469A5 (enExample)
JP2012097380A5 (enExample)
JP2011519893A5 (enExample)
JP2013231197A5 (enExample)
JP2014232319A5 (enExample)
Fragou et al. Epigenetic mechanisms in nanomaterial toxicity
JP2011212925A5 (enExample)